Novo Nordisk shares were under pressure on Monday as the struggling Danish pharmaceutical said a head-to-head study found a drug in development didn’t cut as much weight as an Eli Lilly product.
Novo Nordisk pitted a new weight-loss drug against Eli Lilly — and lost
Related Posts
Popular News
Latest News
Institutional crypto is getting quieter and more serious
Disclosure: The views and opinions expressed here belong solely to the author and do not represent the views and opinions...
Merck to create separate cancer business as Keytruda patent loss looms
Merck to create separate cancer business as Keytruda patent loss looms
L&G enters $1bn strategic partnership with Enosis Capital
Legal & General (L&G) has entered a strategic partnership with Enosis Capital, committing up to $1bn (£740m) over the next...
Gilead shows its belief in its partner’s cancer treatment with a $7.8 billion buyout
Arcellx’s stock is heading toward a record after the $7.8 billion deal to be acquired by Gilead.
Welcome to Global Finances Daily, your go-to source for all things finance. Our mission is to provide our readers with valuable information and insights to help them achieve their financial goals and secure their financial future.